» Articles » PMID: 18541723

PGE2 Induces Angiogenesis Via MT1-MMP-mediated Activation of the TGFbeta/Alk5 Signaling Pathway

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2008 Jun 11
PMID 18541723
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The development of a new vascular network is essential for the onset and progression of many pathophysiologic processes. Cyclooxygenase-2 displays a proangiogenic activity in in vitro and in vivo models, mediated principally through its metabolite prostaglandin E(2) (PGE(2)). Here, we provide evidence for a novel signaling route through which PGE(2) activates the Alk5-Smad3 pathway in endothelial cells. PGE(2) induces Alk5-dependent Smad3 nuclear translocation and DNA binding, and the activation of this pathway involves the release of active TGFbeta from its latent form through a process mediated by the metalloproteinase MT1-MMP, whose membrane clustering is promoted by PGE(2). MT1-MMP-dependent transforming growth factor beta (TGFbeta) signaling through Alk5 is also required for PGE(2)-induced endothelial cord formation in vitro, and Alk5 kinase activity is required for PGE(2)-induced neovascularization in vivo. These findings identify a novel signaling pathway linking PGE(2) and TGFbeta, 2 effectors involved in tumor growth and angiogenesis, and reveal potential targets for the treatment of angiogenesis-related disorders.

Citing Articles

Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis.

Lucarini L, Durante M, Sgambellone S, Lanzi C, Bigagli E, Akgul O Biomolecules. 2020; 10(9).

PMID: 32927723 PMC: 7564963. DOI: 10.3390/biom10091307.


An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer.

Xia H, Yu W, Liu M, Li H, Pang W, Wang L Oncol Lett. 2019; 18(3):2985-2994.

PMID: 31452777 PMC: 6704324. DOI: 10.3892/ol.2019.10669.


Bioactive lysolipids in cancer and angiogenesis.

Hisano Y, Hla T Pharmacol Ther. 2018; 193:91-98.

PMID: 30048709 PMC: 6309747. DOI: 10.1016/j.pharmthera.2018.07.006.


Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Wang X, Khalil R Adv Pharmacol. 2018; 81:241-330.

PMID: 29310800 PMC: 5765875. DOI: 10.1016/bs.apha.2017.08.002.


Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Liu J, Khalil R Prog Mol Biol Transl Sci. 2017; 148:355-420.

PMID: 28662828 PMC: 5548434. DOI: 10.1016/bs.pmbts.2017.04.003.